 Alzheimer's disease, AD, is a global health problem that is difficult to cure. Drugs aimed at slowing the progression of the disease have been developed and approved by the Food and Drug Administration, FDA. A systematic review and meta-analysis were conducted to assess the efficacy and safety of FDA-approved anti-ameloid, anti-A, monoclonal antibodies, MABS, for the treatment of AD. The study identified six randomized controlled trials, RCTs, with a total of 4,471 patients who met the inclusion criteria. FDA-approved anti-A MABS showed statistically significant improvements in clinical outcomes, including CDOSB, ADCS-ADLMCI, ADCMS, and ADISCOG. Additionally, these MABS increased cerebrospinal fluid, CSF, A142 and plasma A42-40 ratios, DECRAE. This article was authored by Winshua Wu, Yiji, Zilan Wang, and others. We are article.tv, links in the description below.